b2/20220119085815okyddzEyf6.png){kind=small}
Arcutis Biotherapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
3027 Townsgate Rd Ste 300, Westlake Vill...Phone Number
(805) 418-5006Website
www.arcutis.comRevenue
$464 MillionStock Symbol
ARQTIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis' dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp psoriasis, atopic dermatitis, and seborrheic dermatitis.Explore more
Arcutis Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arcutis Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Arcutis Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Arcutis Biotherapeutics
Check out if Arcutis Biotherapeutics is spiking on competitors!
Arcutis Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Arcutis Biotherapeutics launches new products
Click to see if Arcutis Biotherapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Arcutis Biotherapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Arcutis Biotherapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined Arcutis Biotherapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Arcutis Biotherapeutics
Compare insights from companies similar to Arcutis Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Arcutis Biotherapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Arcutis Biotherapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Arcutis Biotherapeutics.
Arcutis Biotherapeutics financials insights
Gather financial insights about Arcutis Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$13.5M
2018
Series B
$58M
2019
Series C
$94.5M
2021
Debt
$225M
Arcutis Biotherapeutics Tech Stack
A closer look at the technologies used by Arcutis Biotherapeutics
See more technologies
Most Recent Scoops
Project
Arcutis Biotherapeutics has announced that the FDA accepted a supplemental NDA for ZORYVE Cream 0.05% for mild to moderate atopic dermatitis in infants as young as 3 months, with a PDUFA date set for February 23, 2027.
Product Development, Pharmaceuticals
Hiring Plans
Arcutis Biotherapeutics has announced the completion of Phase 1 of its primary care and pediatric sales force build-out, with the team expected to be in the field by the end of August 2026, focused on high-volume, early-adopter primary care physicians and pediatricians in major metropolitan areas, with impact anticipated by 2027.
Sales, Doctors / Physicians
Project
Arcutis Biotherapeutics has announced the launch of a Virtual Health Platform in June 2026, through which board-certified independent dermatologists evaluate, diagnose, and prescribe ZORYVE, with prescriptions coordinated through a national pharmacy hub with insurance support and at-home delivery, designed to address barriers such as long wait times and geographic gaps in dermatology access.
Pharmaceuticals, Customer Experience, Telemedicine
Partnership
Arcutis Biotherapeutics has partnered with a leading AI-enabled prescription workflow platform widely adopted across dermatology offices to streamline the post-prescription process, including prior authorization, financial assessment, and fulfillment routing embedded into healthcare provider workflows, while providing patients real-time visibility into prescription status.
Partnership, Artificial Intelligence, Healthcare Technology
Hiring Plans
Hiring Plans, Sales, Field /Outside Sales
Arcutis Biotherapeutics News & Media
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Arcutis today announced that management will present at the Morgan Stanley 24th Annual Global Healthcare Conference, taking place September 14-16, 2026.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 143,500 restricted stock units (RSUs) of Arcutis’ common stock as well as options to purchase an aggregate of 37,000 shares of Arcutis’ common stock to 24 newly hired employees. These awards were approved by the Compensation Committee oArcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability
Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence.Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsBrian Schoelkopf - Head of Investor RelationsTodd...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Arcutis Biotherapeutics
Sign Up For FreeTo access detailed company insights
Arcutis Biotherapeutics, Inc. is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis harnesses our unique dermatology development pl... Read More
